ImmunoPrecise Antibodies (IPA) has entered a strategic partnership with Ribopro to transform therapeutic antibody discovery and development.
The partnership will combine the mRNA [messenger ribonucliec acid]-based antigen expression expertise of Ribopro with the in silico and wet-lab antibody discovery capabilities of IPA.
Go deeper with GlobalData
Utilising Ribopro’s mRNA sequence optimisation and lipid nanoparticle-based delivery expertise alongside IPA’s single-cell analysis, B-cell screening and deep-learning AI-powered discovery workflows, the partnership focuses on expediting and improving the development of therapeutics by antigen presentation improvement and immune responses enhancement.
The use of Ribopro’s mRNA and lipid-based nanoparticle technologies within the collaboration allows for efficient antigen expression, potentially leading to immune responses and strengthening the path to discovering new antibody therapeutics.
IPA’s strategy melds AI-driven analytics with specialised wet-lab methodologies to design and optimise antibodies with clinical relevance.
ImmunoPrecise Antibodies chief scientific officer Dr Ilse Roodink stated: “We are enthusiastic to expand our toolbox for the discovery of novel therapeutic antibodies with a state-of-the-art mRNA immunisation platform in this alliance.
“Combining Ribopro’s and IPA’s unique expertise further strengthens our commitment to be at the forefront of solving complex challenges with innovative and high-quality solutions.”
Based in the Netherlands and founded in 2020, Ribopro is a technology and service provider focusing on the development and manufacture of mRNA and LNPs.
Through subsidiaries such as BioStrand, ImmunoPrecise Antibodies in Canada and Europe, and Talem Therapeutics, IPA offers a solution for developing antibody therapeutics.
By integrating multi-omics modelling, systems biology and AI, IPA allows for the discovery of fully human therapeutic antibodies for complex disease targets.
